Alpine Immune Sciences, Inc.

NASDAQ:ALPN

64.97 (USD) • At close May 17, 2024
Bedrijfsnaam Alpine Immune Sciences, Inc.
Symbool ALPN
Munteenheid USD
Prijs 64.97
Beurswaarde 4,456,779,835
Dividendpercentage 0%
52-weken bereik 8.33 - 65
Industrie Biotechnology
Sector Healthcare
CEO Dr. Mitchell H. Gold M.D.
Website https://www.alpineimmunesciences.com

An error occurred while fetching data.

Over Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and

Vergelijkbare Aandelen

Precigen, Inc. logo

Precigen, Inc.

PGEN

0.937 USD

AC Immune SA logo

AC Immune SA

ACIU

3.11 USD

ESSA Pharma Inc. logo

ESSA Pharma Inc.

EPIX

5.74 USD

Tenaya Therapeutics, Inc. logo

Tenaya Therapeutics, Inc.

TNYA

1.91 USD

AN2 Therapeutics, Inc. logo

AN2 Therapeutics, Inc.

ANTX

1.08 USD

SOPHiA GENETICS SA logo

SOPHiA GENETICS SA

SOPH

3.33 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)